CAR-T therapy-associated infections in hematologic malignancies: a real-world pharmacovigilance analysis - PubMed
6 hours ago
- #CAR-T therapy
- #infection risk
- #pharmacovigilance
- Analysis of FDA Adverse Event Reporting System (FAERS) data shows 17.6% of CAR-T therapy reports involve infections, with 2142 infection-related events.
- Infections post-CAR-T therapy have a median time to onset of 6 days and include bacterial, viral, fungal, organ-specific, and other types.
- High-risk, fatal infections linked to CAR-T therapy are sepsis-related, fungal, and Gram-negative bacterial infections, often associated with immune dysregulation.